Equity Profile

SRRK

Scholar Rock Holding Corporation

Health CareBiotechnology$6.6B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Scholar Rock Holding Corporation is a biotechnology company focused on developing therapies for serious diseases by targeting the growth factors that regulate cell behavior. With a market cap of $7 billion, its innovations could significantly impact the health care sector, particularly in treating conditions related to muscle and nerve disorders.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth will provide insight into the company's market traction and demand for its therapies.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

SRRK Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

-11.44%

Avg Stock Reaction

+0.88%

Last Quarter Recap

In Q1 2026, Scholar Rock reported an EPS of -$0.83, slightly missing expectations. The stock reacted negatively, declining by 1.40% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Scholar Rock's upcoming earnings are uncertain, given the lack of analyst estimates and mixed historical performance.

Bull Case

If the company can demonstrate strong clinical trial results and improved revenue metrics, it may attract positive investor sentiment and drive the stock higher.

Bear Case

Conversely, if the company fails to show progress in its clinical trials or continues to report losses, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What updates can management provide on the progress of ongoing clinical trials?

Investors will be keen to understand the potential for future therapies and how they may impact revenue.

How does the company plan to address its ongoing losses and improve profitability?

Management's strategy for financial health will be crucial for investor confidence moving forward.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of upcoming clinical trial results, which could drive significant revenue growth.

Supporting Evidence

The options market is pricing a 13.4% move, indicating expectations of volatility that may not align with historical performance.

The company's recent history shows a pattern of stock recovery following earnings misses, suggesting resilience.

Key Risk

If clinical trial results exceed expectations, it could shift the narrative and lead to a positive reassessment of the company's prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the company's potential for growth against its current financial struggles.

Bull Confirmed If

Demonstrating significant progress in clinical trials and a clear path to profitability would confirm the bull case.

Bear Confirmed If

Continued losses without a clear strategy for improvement would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±13.4%

Historical Avg

±5.7%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±13.4% while SRRK has averaged ±5.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

36.3%

Calls (38K)P/C Ratio: 0.08Puts (6K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Scholar Rock beats expectations and raises guidance, history suggests the stock could see an average one-day move of +1.15%.

In-Line / Cautious

If results are in line with expectations but management provides cautious commentary, the stock may experience a muted reaction.

Miss

Should the company miss expectations, history indicates an average one-day move of +1.15%, suggesting potential downside.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of clinical trials and any new data.
2Management's commentary on strategies to improve profitability.
3Insights into market demand for their therapies.
4Any potential partnerships or collaborations in the pipeline.
5Guidance on future revenue expectations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth will provide insight into the company's market traction and demand for its therapies.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

SRRK Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

-11.44%

Avg Stock Reaction

+0.88%

Last Quarter Recap

In Q1 2026, Scholar Rock reported an EPS of -$0.83, slightly missing expectations. The stock reacted negatively, declining by 1.40% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Scholar Rock's upcoming earnings are uncertain, given the lack of analyst estimates and mixed historical performance.

Bull Case

If the company can demonstrate strong clinical trial results and improved revenue metrics, it may attract positive investor sentiment and drive the stock higher.

Bear Case

Conversely, if the company fails to show progress in its clinical trials or continues to report losses, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What updates can management provide on the progress of ongoing clinical trials?

Investors will be keen to understand the potential for future therapies and how they may impact revenue.

How does the company plan to address its ongoing losses and improve profitability?

Management's strategy for financial health will be crucial for investor confidence moving forward.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of upcoming clinical trial results, which could drive significant revenue growth.

Supporting Evidence

The options market is pricing a 13.4% move, indicating expectations of volatility that may not align with historical performance.

The company's recent history shows a pattern of stock recovery following earnings misses, suggesting resilience.

Key Risk

If clinical trial results exceed expectations, it could shift the narrative and lead to a positive reassessment of the company's prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the company's potential for growth against its current financial struggles.

Bull Confirmed If

Demonstrating significant progress in clinical trials and a clear path to profitability would confirm the bull case.

Bear Confirmed If

Continued losses without a clear strategy for improvement would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±13.4%

Historical Avg

±5.7%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±13.4% while SRRK has averaged ±5.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

36.3%

Calls (38K)P/C Ratio: 0.08Puts (6K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Scholar Rock beats expectations and raises guidance, history suggests the stock could see an average one-day move of +1.15%.

In-Line / Cautious

If results are in line with expectations but management provides cautious commentary, the stock may experience a muted reaction.

Miss

Should the company miss expectations, history indicates an average one-day move of +1.15%, suggesting potential downside.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of clinical trials and any new data.
2Management's commentary on strategies to improve profitability.
3Insights into market demand for their therapies.
4Any potential partnerships or collaborations in the pipeline.
5Guidance on future revenue expectations.